Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%

Basit Öğe Kaydı
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorÖzgüroğlu, Mustafa
dc.contributor.authorSezer, Ahmet
dc.contributor.authorGümüş, Mahmut
dc.contributor.authorBondarenko, Igor
dc.contributor.authorGogishvili, Miranda
dc.contributor.authorTurk, Haci M.
dc.date.accessioned2025-06-03T13:32:17Z
dc.date.available2025-06-03T13:32:17Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractCemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%
dc.identifier.citationKilickap, S., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., ... & Magnan, H. (2024). OA11. 06 Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression≥ 50%: 5-y Outcomes of EMPOWER-Lung 1. Journal of Thoracic Oncology, 19(10), S35.
dc.identifier.endpage35
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue10
dc.identifier.scopus2-s2.0-105004431788
dc.identifier.scopusqualityQ1
dc.identifier.startpage35
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7284
dc.identifier.volume19
dc.identifier.wosWOS:001337925600054
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorKılıçkap, Saadettin
dc.institutionauthoridSaadettin Kılıçkap / 0000-0003-1637-7390
dc.language.isoen
dc.publisherJohn wiley and sons inc
dc.relation.ispartofCancer
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAdvanced NSCLC
dc.subjectBrain Metastases
dc.subjectCemiplimab
dc.subjectImmunotherapy
dc.subjectPD-L1
dc.titleCemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death-ligand 1 ≥50%
dc.typeOther

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Diğer Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu